Treatment goals for moderate to severe psoriasis: An Australian consensus

Australasian Journal of Dermatology

Volumn 54, Issue 2, 2013, Pages 148-154

  Baker, Christopher ^a,b   MacK, Alexandra ^b,c   Cooper, Alan ^f,g   Fischer, Gayle ^f,g   Shumack, Stephen ^f,g,h   Sidhu, Shireen ^i,j   Soyer, Peter ^k,l   Wu, Jason ^l   Chan, Jonathan ^m   Nash, Peter ^k   Rawlin, Morton ^a,b,d   Radulski, Barbara ^a,b,e   Foley, Peter ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Skin and Cancer Foundation Inc   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Royal Australasian College of General Practitioners   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

ⁱ ROYAL ADELAIDE HOSPITAL   (Australia)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l PRINCESS ALEXANDRA HOSPITAL   (Australia)

^m SIR CHARLES GAIRDNER HOSPITAL   (Australia)

more..

Author keywords

Australian; DLQI; PASI; psoriasis; quality of life; treatment goal

Indexed keywords

ARTICLE; AUSTRALIA; CONSENSUS; HUMAN; MOTIVATION; OUTCOME ASSESSMENT; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; QUALITY OF LIFE INDEX;

AUSTRALIA; HUMANS; PATIENT CARE PLANNING; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84876296382     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12014     Document Type: Article

References (19)

1. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br. J. Dermatol. 2007; 157: 649-655.
2. Gelfand J, Neimann A, Shin D, et al. Risk of myocardial infarction in patients with psoriasis. J. Am. Med. Assoc. 2006; 296: 1735-1741.
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 1999; 41: 401-407.
4. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch. Dermatol. 2010; 146: 891-895.
5. Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
6. Nast A, Erdmann R, Hofelich V, et al. Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines. Arch. Dermatol. Res. 2009; 301: 553-559.
7. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br. J. Dermatol. 2006; 155: 729-736.
8. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch. Dermatol. Res. 2011; 303: 1-10.
9. Rachmani R, Slavacheski I, Berla M, et al. Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. J. Am. Soc. Nephrol. 2005; 16 (Suppl. 1): S22-26.
10. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
11. Atar D, Birkeland KI, Uhlig T,. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann. Rheum. Dis. 2010; 69: 629-630.
12. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010; 69: 631-637.
13. Gullick NJ, Oakley SP, Zain A, et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology (Oxford) 2012; 51: 759-761.
14. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life-results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137: 280-284.
15. Mukhtar R, Choi J, Koo JY,. Quality-of-life issues in psoriasis. Dermatol. Clin. 2004; 22: 389-395.
16. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual. Life Outcomes 2006; 4: 71.
17. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J. Invest. Dermatol. 2005; 125: 659-664.
18. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J. Eur. Acad. Dermatol. 2010; 24 (Suppl. 2): 17-22.
19. Lewis-Jones MS, Finlay AY,. The children's dermatology life quality index (CDLQI): initial validation and practical use. Br. J. Dermatol. 1995; 132: 942-949.